Fluoroquinolone-Associated Soft Tissue Injury: Pathophysiology, Clinical Spectrum, and Outcomes

Share
Fluoroquinolone-Associated Soft Tissue Injury: Pathophysiology, Clinical Spectrum, and Outcomes
Photo by Alexander Grey / Unsplash

Yoon Hang Kim MD MPH

Board-Certified, Preventive Medicine

Integrative & Functional Medicine

About the Author

Yoon Hang Kim MD MPH is a board-certified preventive medicine physician practicing integrative and functional medicine. He is the author of eight books, including LDN Primer, LDN for Clinicians, MCAS: Epidemic in Plain Sight, and Integrative Oncology: Evidence-Based Strategies to Support Cancer Treatment, with more than 25 peer-reviewed publications. He completed the University of Arizona Osher Fellowship under Dr. Andrew Weil, holds UCLA medical acupuncture certification, and is a recipient of the IFM Scholarship. He previously served as Enterprise Medical Director at WellMed/Optum, Medical Director of Integrative Oncology at Miami Cancer Institute, and Director of the Integrative Medicine Program at the University of Kansas Medical Center. He founded the LDN Support Group and runs a membership-based telemedicine practice.

Abstract

Background: Fluoroquinolone antibiotics, including ciprofloxacin, levofloxacin, and moxifloxacin, are among the most widely prescribed antimicrobial agents worldwide. Their best-established connective tissue adverse effects are tendinopathy and tendon rupture, but concern has grown that fluoroquinolone-associated injury may extend to other collagen-dependent structures. This narrative review summarizes the evidence on fluoroquinolone-associated soft tissue injury in humans, distinguishing established clinical effects from epidemiological associations, experimental mechanisms, and plausible but incompletely validated extensions to other tissues.

Methods: This is a narrative review based on targeted literature searches of PubMed, MEDLINE, and the Cochrane Library, with the final search conducted in November 2026 and covering publications from 1992 onward, supplemented by regulatory communications from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Medsafe New Zealand. Sources were prioritized in the following order: regulatory safety communications and advisory committee reports; population-based epidemiological studies reporting adjusted risk estimates; systematic reviews and meta-analyses; and original mechanistic studies in human or animal tissue. It does not follow a formal systematic-review protocol; search strategies and study selection were not pre-registered, and the evidence is synthesized qualitatively.

Results: Experimental studies in cultured tenocytes and animal models have identified several potentially interacting mechanisms, including dysregulation of matrix metalloproteinases (MMPs), oxidative stress with mitochondrial membrane changes, chelation of divalent cations with impaired integrin signaling, altered collagen synthesis and crosslinking, and caspase-3 activation. The strongest human clinical evidence concerns Achilles tendinopathy and rupture, where relative risk is clearly elevated (adjusted incidence rate ratio ~1.6 for any tendon rupture and ~3.1 for Achilles rupture, rising markedly with concurrent oral corticosteroids), while absolute excess risk remains modest at a few additional ruptures per 10,000 person-years. The association between fluoroquinolones and aortic aneurysm or dissection remains genuinely contested, with several large cohort studies and meta-analyses reporting increased risk and others finding none. A subset of patients report prolonged multisystem symptoms described in pharmacovigilance literature as fluoroquinolone-associated disability (FQAD), a construct whose incidence, mechanism, and natural history remain incompletely characterized.

Conclusions: Fluoroquinolone-associated tendon injury is a well-established, clinically important adverse effect. Experimental findings raise the plausibility of broader connective tissue involvement, but direct human evidence for ligamentous, fascial, and cartilaginous injury is limited, and the aortic association remains uncertain. No established therapy reliably reverses persistent multisystem toxicity. Prescribing should reflect infection severity, antimicrobial susceptibility, patient-specific risk factors, and the availability of effective alternatives.

Keywords: fluoroquinolones, tendinopathy, tendon rupture, matrix metalloproteinases, oxidative stress, fluoroquinolone-associated disability, FQAD, aortic aneurysm, absolute risk, connective tissue

1. Introduction

Fluoroquinolone antibiotics are among the most widely prescribed antimicrobial classes in modern medicine. Ciprofloxacin, levofloxacin, and moxifloxacin collectively account for tens of millions of outpatient prescriptions annually in the United States, although this figure declined from approximately 35.6 million in 2015 to 21.1 million in 2019 following successive regulatory warnings [1,2]. These agents inhibit bacterial DNA gyrase and topoisomerase IV, achieving broad-spectrum bactericidal activity.

Since the first published report of fluoroquinolone-associated tendinopathy in two renal transplant patients receiving norfloxacin in 1983 [3], a substantial body of evidence has established tendon injury as a recognized adverse effect of this class. The central question this review addresses is how far that evidence extends: whether the connective tissue toxicity demonstrated for tendons also produces clinically significant injury in other collagen-rich structures such as ligaments, fascia, cartilage, and the aortic wall. Throughout, the aim is to separate established human clinical effects from epidemiological associations with unresolved confounding, experimental mechanisms demonstrated only in cells or animals, and plausible but unproven extensions to other tissues.

Drug-induced soft tissue injury is a distinct subset of the broader spectrum of connective tissue disorders affecting tendons, bursae, ligaments, and fasciae [4], in which a pharmacological agent rather than mechanical loading initiates the pathological process [5]. Situating fluoroquinolone toxicity within this framework helps clinicians evaluate unexplained musculoskeletal complaints after antibiotic exposure.

The regulatory history of the class reflects progressive recognition of these effects. The FDA issued a black box warning for tendinitis and tendon rupture in 2008, expanded it in 2016 to include disabling and potentially permanent effects on tendons, muscles, joints, nerves, and the central nervous system, and added a warning for aortic aneurysm and dissection in 2018 [6,7,8]. The EMA and other national regulators have implemented parallel restrictions. Despite these warnings, clinical awareness that fluoroquinolone injury is not solely an Achilles tendon problem remains incomplete—the premise this review develops, while taking care not to overstate the evidence for tissues beyond the tendon.

2. Experimental Mechanisms of Fluoroquinolone Connective Tissue Toxicity

Experimental work has identified several potentially interacting pathways by which fluoroquinolones disrupt extracellular matrix (ECM) homeostasis. The strength of evidence differs substantially among them, and most derive from cultured cells or animal models rather than from human tissue sampled after therapeutic exposure. These mechanisms are best read as biologically plausible contributors rather than as established causes of clinical injury.

2.1 Tissue Pharmacokinetics

A relevant question is whether therapeutic dosing produces drug concentrations in connective tissue comparable to those used in laboratory studies. Using microdialysis, Bellmann et al. measured levofloxacin concentrations in human subcutaneous adipose tissue after a single 500 mg intravenous dose, reporting mean peak extracellular concentrations of roughly 5 mg/L (somewhat higher in inflamed than in healthy tissue) with considerable interindividual variability [9]. These values overlap the concentration range (3–10 mg/L) used in some experimental tenocyte studies. However, the study measured subcutaneous tissue penetration, not tendon concentrations, and did not assess collagen degradation, tenocyte apoptosis, or tissue injury. These data therefore support the pharmacokinetic plausibility of connective tissue exposure but do not establish cytotoxic drug levels within tendon or demonstrate injury in vivo.

2.2 Matrix Metalloproteinase Dysregulation

Among the proposed mechanisms, MMP dysregulation is the best supported by experimental tenocyte research. MMPs are zinc-dependent endopeptidases that remodel ECM. Corps et al. showed that ciprofloxacin selectively enhanced MMP-3 expression in human tendon-derived cells in the presence of interleukin-1β, suggesting amplification of an existing degradative cascade rather than its initiation [10], and reported contrasting effects of different fluoroquinolones on the collagenases MMP-1 and MMP-13 [11]. Sendzik et al. observed time- and concentration-dependent increases in MMP expression in human tenocytes exposed to ciprofloxacin and levofloxacin at 3–10 mg/L, with concurrent decreases in type I collagen and β1-integrin [12,13]. The net effect in these models is a shift of the MMP/TIMP balance toward matrix degradation; whether this translates into reduced tissue tensile strength in vivo has not been directly demonstrated.

2.3 Oxidative Stress and Mitochondrial Changes

Several cellular studies implicate oxidative stress. Lowes et al. reported that ciprofloxacin and moxifloxacin produced up to a 3-fold increase in oxidative stress markers in human Achilles tendon cells, with loss of mitochondrial membrane potential that was attenuated by the mitochondria-targeted antioxidant MitoQ [14]. Pouzaud et al., using a spontaneously immortalized rabbit tendon cell line, found that fluoroquinolone toxicity to tendon cells involved early oxidative stress and varied in intensity among agents, with ciprofloxacin and pefloxacin most toxic [15]. In rodents, pefloxacin induced oxidative damage to type I collagen in the Achilles tendon [16], and a 2024 study in a murine tendon cell line (TT-D6) reported decreased collagen XII expression with increased reactive oxygen species after levofloxacin exposure [17]. Michalak et al. proposed that cation chelation disrupts mitochondrial function, generating a self-amplifying oxidative cycle [18]. These findings are mechanistically compelling at the cellular level, but their contribution to persistent human disability remains a hypothesis rather than an established fact.

A collaborative investigation by Kaur et al., combining scientific analysis with reports from a fluoroquinolone adverse-event social network, characterized neuropsychiatric and mitochondrial toxicity and illustrated the value of patient-reported data in pharmacovigilance, while sharing the interpretive limits inherent to spontaneous reporting [19].

2.4 Divalent Cation Chelation and Integrin Signaling

Fluoroquinolones chelate divalent cations including magnesium, calcium, iron, and zinc. Because β1-integrin requires Mg²⁺ for activation and binding to ECM ligands [20], cation depletion could impair integrin-mediated adhesion and focal adhesion kinase signaling, with downstream effects on MAPK/ERK survival pathways and a tendency toward apoptosis [21]. Demonstrating drug–cation interactions in vitro does not, however, establish clinically significant intracellular magnesium depletion during therapy; this pathway remains plausible but unproven as a driver of human injury.

2.5 Collagen Synthesis and Crosslinking

Fluoroquinolones may also affect new collagen formation, although the data are more heterogeneous than is sometimes appreciated. In a rabbit tenocyte model, Bernard-Beaubois et al. found that fluoroquinolone exposure compromised tenocyte function despite relatively preserved type I collagen mRNA [22]. Menon et al. examined extracellular matrix remodeling and collagen turnover pathways in cultured human tenocytes after ciprofloxacin administration and reported heterogeneous changes: type I and III collagen mRNA and protein levels were not significantly altered, while lysyl hydroxylase 2b and TIMP-1 expression showed a trend toward reduction [23]. Because lysyl hydroxylase 2b contributes to hydroxylysine-based collagen crosslinking, these findings suggest possible impairment of collagen maturation and matrix homeostasis, though the relationship to clinical tendon strength remains unestablished and the observed changes were not uniformly significant. Histological descriptions of fluoroquinolone-exposed tendons report disorganized collagen, hypercellularity, and increased glycosaminoglycan content consistent with a degenerative rather than inflammatory process [23].

2.6 Tenocyte and Stem Cell Apoptosis

Sendzik et al. demonstrated concentration-dependent caspase-3 activation in human tenocytes exposed to ciprofloxacin and levofloxacin, with apoptotic morphology on electron microscopy [13]. Arif et al. reported dose-dependent apoptosis and elevated caspase-3 expression in rat bone marrow mesenchymal stem cells exposed to levofloxacin, with TIMP-3 and Col1A1 expression unaffected, raising the possibility of impaired regenerative capacity [24]; it should be emphasized that these were rat-derived rather than human stem cells, which limits direct clinical extrapolation. Caspase-3 activation in cultured cells does not establish the magnitude or persistence of apoptosis in human tendon after therapeutic exposure. Synthesizing these lines of evidence, Bisaccia et al. described five candidate mechanisms—arrested proliferation, reduced tenocyte migration, decreased collagen synthesis, increased MMP activity, and apoptosis—while emphasizing that the dose–effect and structure–damage relationships remain incompletely defined [21].

3. Clinical Spectrum and the Strength of Human Evidence

The clinical evidence varies markedly by tissue. Table 1 summarizes this gradient, which is central to interpreting the literature responsibly: susceptibility based on shared biology is not the same as demonstrated clinical injury.

Table 1. Gradient of evidence for fluoroquinolone-associated soft tissue injury by tissue and syndrome.

Tissue / Syndrome

Nature & strength of evidence

Principal limitation

Achilles tendinopathy / rupture

Strong human epidemiological and clinical evidence

Absolute risk low; concentrated in susceptible groups

Other-site tendon injury

Documented in case reports and series

Site-specific evidence varies in quantity and quality

Diffuse musculoskeletal symptoms

Recognized clinical adverse effects

Precise tissue pathology often uncertain

Ligament / fascial injury

Biologically plausible; shared cell biology

Direct human evidence limited

Cartilage toxicity

Stronger preclinical evidence, esp. immature animals

Human clinical correlate less established

Aortic aneurysm / dissection

Regulatory warning; conflicting observational signals

Causality and effect magnitude debated

Persistent multisystem FQAD

Documented reports; regulatory recognition

Incidence, mechanism, natural history uncertain

3.1 Tendon Injury

Tendinopathy and rupture are the best-characterized complications, most often involving the Achilles tendon, though other sites including the rotator cuff, quadriceps, patellar, gluteal, and hand tendons are reported [25]. A 2025 case report described a non-traumatic partial tear of the gluteus medius tendon at the greater trochanter, with associated trochanteric bursitis, following a 5-day ciprofloxacin course [26], illustrating that loaded tendons at various sites may be vulnerable. Bilateral Achilles rupture, while rare, is a recognized presentation; Akali and Niranjan reported such a case with ciprofloxacin and reviewed the reconstructive and rehabilitative challenges [27]. Bilateral presentation should raise suspicion for a pharmacological etiology, as simultaneous traumatic rupture of both Achilles tendons is uncommon.

Relative and absolute risk should be considered together, because relative risks alone can give a misleading impression that rupture is common. In one large population-based nested case–control study, Morales et al. found an adjusted incidence rate ratio of 1.61 (95% CI 1.25–2.09) for any tendon rupture and 3.14 (95% CI 2.11–4.65) for Achilles rupture during current fluoroquinolone use; concurrent oral corticosteroid and fluoroquinolone exposure was associated with a markedly increased risk of Achilles rupture (adjusted IRR 19.36; 95% CI 7.78–48.19), though the wide confidence interval indicates substantial imprecision and this estimate should not be treated as a universal risk multiplier applicable to every patient [29]. The absolute excess risk is modest: a United Kingdom cohort analysis estimated roughly 3.7 additional tendon ruptures and 2.9 additional Achilles ruptures per 10,000 person-years with current fluoroquinolone use, rising substantially with concomitant corticosteroids [30]. The practical message is that fluoroquinolone tendon toxicity is clinically important chiefly because risk is strongly amplified in identifiable susceptible groups, not because rupture is frequent in the general population.

The temporal profile is also informative: most patients present within one month of initiating therapy, but a substantial proportion develop symptoms after the drug is stopped, and rupture has been reported months after cessation [25]. Older reports suggest roughly half of tendon cases improve within 30 days while a quarter have symptoms beyond two months [28]; these tendon-specific figures should not be generalized to multisystem presentations.

3.2 Ligament, Fascia, and Cartilage

Evidence for non-tendon connective tissue injury is weaker and more indirect. Animal studies demonstrate high-affinity fluoroquinolone binding to cartilage and bone, with cartilage lesions in juvenile animals [31]. This preclinical cartilage toxicity has contributed to longstanding restrictions and caution regarding pediatric fluoroquinolone use. It is important to state this accurately: fluoroquinolones are not categorically contraindicated in children. Selected agents retain approved pediatric indications—ciprofloxacin, for example, is labeled for complicated urinary tract infection and pyelonephritis in patients aged 1 to 17 years, and for inhalational anthrax post-exposure prophylaxis and plague in adult and pediatric patients—where expected benefits outweigh potential risks. They are generally not first-choice pediatric agents because of these adverse-event concerns.

Clinically, fluoroquinolone exposure is associated with arthralgia, joint swelling, and diffuse musculoskeletal pain [32], symptoms that overlap the broader category of soft tissue syndromes [4] but whose precise tissue pathology is often uncertain. Although articular cartilage, ligaments, and fascia share the collagen-dependent architecture and fibroblast populations implicated in tendon toxicity, direct human evidence of drug-induced ligamentous or fascial injury remains limited. The reasonable conclusion is that these tissues are biologically plausible targets for which clinical injury has not been well characterized, rather than established sites of fluoroquinolone damage.

3.3 Aortic Aneurysm and Dissection

The aortic wall is collagen-rich, providing biological rationale for concern, but the epidemiological evidence is genuinely conflicting. Several analyses report increased risk. A 2021 meta-analysis found elevated odds of aortic dissection (OR 2.38; 95% CI 1.71–3.32) and aneurysm (OR 1.98; 95% CI 1.59–2.48) [33]; a 2024 review reached similar conclusions [34]; a 2025 German propensity-score–matched cohort study reported a significantly higher risk versus macrolides (adjusted hazard ratio 1.52; 95% CI 1.33–1.74), robust across agents and exposure windows [35]; and a 2026 meta-analysis of cohort studies found a pooled hazard ratio of approximately 1.20 (95% CI 1.06–1.35) [36]. A separate systematic review and meta-analysis of 13 studies incorporating more than 36 million participants reported a higher short-term combined risk of aortic aneurysm or dissection following fluoroquinolone administration; in subgroup analyses, aortic dissection and aneurysm risks were largely comparable, although de novo aneurysm risk was significantly increased at 30 and 60 days [37]. These mixed subgroup results illustrate how sensitive the findings are to outcome definition and observation window.

Other large studies have not confirmed an association. A nationwide Korean population-based analysis found no significant difference in aortic aneurysm or dissection between recipients of fluoroquinolones and third-generation cephalosporins, concluding that fluoroquinolone use should not be deterred when clinically indicated [38]. A 2025 Danish nationwide nested case–control study paralleled with matched experimental models likewise did not demonstrate increased risk or aortic enlargement [39]. Even among positive studies, absolute event rates are low: a Swedish nationwide cohort reported 1.2 aortic aneurysm or dissection cases per 1,000 person-years among fluoroquinolone users versus 0.7 per 1,000 person-years among amoxicillin users within a 60-day risk window [40]. Ciprofloxacin has been shown in vitro to accelerate angiotensin-II–induced vascular smooth muscle cell senescence [41], offering a candidate mechanism.

Taken together, the evidence suggests a possible association between fluoroquinolone exposure and aortic aneurysm or dissection, but the magnitude and causal nature of this relationship remain uncertain. Differences in comparator selection, infection severity, baseline cardiovascular risk, geographic setting, and observation periods may contribute to inconsistent findings. Mechanistic experiments provide biological plausibility but cannot independently establish clinical causation. Current regulatory warnings support particular caution in patients with established aortic disease or recognized risk factors. Antibiotic selection should remain individualized, integrating infection severity, antimicrobial susceptibility, patient-specific vulnerabilities, and the availability of effective alternatives.

4. Fluoroquinolone-Associated Disability (FQAD)

FQAD describes a pattern of persistent, multisystem adverse effects reported after fluoroquinolone exposure. The operational definition—adverse events in two or more organ systems (musculoskeletal, neuropsychiatric, peripheral nervous, sensory, skin, or cardiovascular) lasting at least 30 days after discontinuation—was advanced by an FDA epidemiologist in 2015 and is useful for identifying persistent reports [1]. FQAD is, however, a pharmacovigilance construct rather than a fully validated diagnostic syndrome with a single proven pathophysiology; the definition does not establish that all cases share one mechanism, and the syndrome is not formally recognized as a distinct clinical entity.

The FDA's review of FAERS reports (1997–2015) identified 1,122 reports of disability associated with recent prior fluoroquinolone use, of which 178 met the FQAD criteria. Among those 178, 78% were female and 74% were aged 30–59, with about a quarter reporting disability exceeding one year and the longest reported duration being nine years [1]. These are spontaneous reports: they demonstrate the reported spectrum and potential duration of injury but cannot establish incidence, typical prognosis, or causation. A 2024 case report described a 41-year-old man who developed bilateral extremity numbness and tingling after two doses of ciprofloxacin and underwent 18 months of extensive evaluation without diagnostic clarity, illustrating how such patients are often undiagnosed and subjected to costly testing [42]. A large German claims-based cohort study found an increased risk of neurological and neuropsychiatric events after fluoroquinolone exposure, especially within the first 92 days, with variation by age and sex [43].

Although experimental studies implicate mitochondrial dysfunction, oxidative stress, and ECM changes, no single mechanism has been established to explain the full clinical presentation; mitochondrial injury should be understood as a research hypothesis rather than a proven unifying cause. The heterogeneity of symptoms, limited prospective data, and absence of validated biomarkers complicate both diagnosis and prognostication. Attribution is a particular challenge: persistent fatigue, neuropathy, cognitive symptoms, and musculoskeletal pain have many causes, and pre-existing neuropathy, autoimmune disease, chronic pain syndromes, thyroid and metabolic disorders, and mood disorders should be actively considered in the differential rather than assumed to be drug-induced. A careful exposure timeline—agent, dose, dates, and symptom onset relative to therapy—is the most useful diagnostic tool available. Framing FQAD in this way does not minimize patients' experiences; it makes the clinical approach more reproducible.

5. Risk Factors and Vulnerable Populations

Recognized risk factors for tendon injury include age over 60, concurrent systemic corticosteroid use, renal impairment, solid organ transplantation, and pre-existing tendon disorders [1,3,25]. The interaction with corticosteroids is the most clinically actionable, and warrants particular caution when co-prescribing [29]. Athletes may represent an additional at-risk group because of repetitive tendon loading [31]. Serious reactions, including persistent multisystem symptoms, have nonetheless been reported in otherwise healthy individuals without recognized risk factors and after short courses [1,42], suggesting that unidentified host susceptibility factors—potentially involving drug metabolism, mitochondrial variants, or antioxidant capacity—may contribute.

6. Regulatory Response

2008: First black box warning for tendinitis and tendon rupture [6].

2011: Worsening of myasthenia gravis added to the boxed warning.

2013: Warning that peripheral neuropathy may be irreversible [8].

2016: Expanded black box warning for disabling, potentially permanent effects; advice to restrict use for uncomplicated sinusitis, bronchitis, and UTI [7].

2018: Added warnings for aortic aneurysm and dissection, hypoglycemia, and mental health effects [8].

2025: New Zealand's Medicines Adverse Reactions Committee reviewed systemic fluoroquinolone safety and recommended data sheet updates stating that serious, prolonged, and disabling reactions—including tendonitis and tendon rupture, peripheral neuropathy, and psychiatric reactions—are potentially irreversible, together with a risk–benefit statement in the indications [46,47].

Fluoroquinolone prescribing declined after the 2016 FDA warning, though overuse for uncomplicated infections persists [1,2].

7. Management and Investigational Therapies

It is useful to distinguish three clinical situations: immediate management of suspected acute toxicity, rehabilitation of established tendon injury, and investigational approaches to persistent multisystem symptoms.

Immediate management. If tendon pain, swelling, new neuropathic symptoms, weakness, or significant mental status changes develop during therapy, the fluoroquinolone should be stopped promptly and an appropriate alternative arranged; the affected area should be protected from loading until evaluated, since rupture can occur during or after treatment [7]. After a serious reaction, subsequent fluoroquinolone use should be avoided and the specific drug and reaction documented.

Assessment and rehabilitation. Management should be staged according to the clinical picture, distinguishing uncomplicated tendinopathy, suspected partial tear, and complete rupture. Where rupture or significant structural injury is suspected—sudden pain with a palpable gap, loss of function, or an audible snap—ultrasound or MRI is appropriate to define the lesion and guide management; complete rupture warrants prompt orthopedic referral. For uncomplicated tendinopathy, initial load reduction is reasonable, with rehabilitation progressively individualized according to symptoms, structural findings, and functional tolerance. Both unrestricted early tendon loading and prolonged immobilization without a clear indication should be avoided. Fluoroquinolone-associated tendinopathy may respond less predictably to conventional eccentric-loading protocols than non-drug-induced tendinopathy, which argues for a graded and closely monitored approach [28].

Investigational approaches for persistent symptoms. No established therapy reliably reverses chronic multisystem toxicity. Mechanistic reviews propose antioxidant, mitochondrial, and cation-repletion strategies [18], but the supporting evidence is largely preclinical. A 2025 randomized pilot of vitamin E and selenium for prevention of fluoroquinolone-induced tendinopathy enrolled roughly 25 patients; it reported improvements in pain and function, but the difference in tendinopathy incidence between groups did not reach statistical significance, making it hypothesis-generating rather than evidence of effective prevention [44]. Empiric supplementation carries risks warranting caution: vitamin E at higher doses may increase bleeding risk in patients taking anticoagulants or antiplatelet agents, and selenium has a narrow margin of safety in excess. A rodent study reporting dexamethasone-associated antioxidant protection against fluoroquinolone tendon damage [45] should not be read as clinical support for corticosteroid treatment, particularly given the strong established association between concurrent corticosteroids and tendon rupture [29].

New Zealand's 2025 regulatory review noted limited data on persistence and irreversibility and confirmed that no proven treatment exists for prolonged disabling reactions [46]. For individual patients, the most useful details remain the specific agent, exposure dates, symptom onset, and whether the predominant problem is tendon injury, neuropathy, neuropsychiatric symptoms, or a combination.

8. Clinical Implications

First, fluoroquinolone injury is not solely an Achilles tendon problem; other tendon sites and, less certainly, other connective tissues may be affected, so unexplained musculoskeletal or connective tissue symptoms after exposure merit a broad differential—while recognizing that evidence beyond the tendon is limited.

Second, the corticosteroid interaction is the most clinically actionable modifiable risk factor and should prompt particular caution when co-prescribing [29].

Third, bilateral tendon rupture should raise suspicion for a pharmacological etiology and prompt immediate discontinuation and documentation [27].

Fourth, in patients with established aortic disease or other recognized risk factors, the uncertain but unresolved aortic signal supports careful risk assessment and preferential use of alternatives where clinically reasonable [35,39].

Fifth, fluoroquinolone prescribing should reflect infection severity, antimicrobial susceptibility, patient-specific risk factors, and the availability of effective alternatives. For the uncomplicated infections covered by FDA restrictions—acute sinusitis, acute bronchitis, and uncomplicated urinary tract infection—use should generally be reserved for patients without suitable alternatives [7]. Fluoroquinolones may remain appropriate for selected serious or complicated infections when supported by susceptibility data, tissue penetration, and clinical circumstances.

9. Conclusion

Fluoroquinolone-associated tendinopathy and tendon rupture are well-established adverse drug effects with important clinical consequences. Experimental studies have identified several potentially interacting mechanisms, including altered extracellular matrix remodeling, increased matrix metalloproteinase activity, oxidative stress, mitochondrial dysfunction, impaired cell–matrix signaling, and tenocyte apoptosis, though the strength of evidence varies across pathways.

Although tendon injury remains the best-characterized complication, these findings raise the possibility of broader effects on other collagen-rich structures. Evidence for direct ligamentous, fascial, and cartilaginous injury in humans remains limited. The association between fluoroquinolone exposure and aortic aneurysm or dissection is supported by regulatory warnings and several observational studies, but conflicting epidemiological findings leave its magnitude and causality uncertain.

A subset of patients report prolonged multisystem adverse effects described as fluoroquinolone-associated disability, a pharmacovigilance construct whose mechanisms, incidence, natural history, and predictors of recovery remain incompletely understood. No established treatment reliably reverses persistent multisystem toxicity, and preliminary investigations of antioxidant and mitochondrial strategies warrant further research without currently supporting routine recommendations.

Clinically, the most important interventions remain appropriate antibiotic selection, recognition of patient-specific risk factors—especially concurrent corticosteroids—early identification of adverse reactions, and individualized management of established injury. Future research should prioritize prospective clinical cohorts, validated measures of persistent toxicity, tissue-specific investigation, and controlled therapeutic trials.

References

1. Bennett AC, Bennett CL, Witherspoon BJ, Knopf KB. An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency. Expert Opin Drug Saf. 2019;18(11):1055–1063. doi:10.1080/14740338.2019.1665022. PMID: 31500468.

2. Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Aust Prescr. 2021;44:161–164. doi:10.18773/austprescr.2021.035.

3. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36(11):1404–1410.

4. Biundo JJ, Mipro RC, Fahey P. Sports-related and other soft-tissue injuries, tendinitis, bursitis, and occupation-related syndromes. Curr Opin Rheumatol. 1997;9(2):151–154.

5. Buckwalter JA, Woo SL. Drug treatment of soft tissue injuries: efficacy and tissue effects. Iowa Orthop J. 1993;13:53–63.

6. U.S. Food and Drug Administration. FDA adds “black box” warning label to fluoroquinolone antibiotics. July 8, 2008.

7. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. July 26, 2016.

8. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. December 20, 2018.

9. Bellmann R, Kuchling G, Dehghanyar P, Zeitlinger M, Minar E, Mayer BX, Müller M, Joukhadar C. Tissue pharmacokinetics of levofloxacin in human soft tissue infections. Br J Clin Pharmacol. 2004;57(5):563–568. doi:10.1111/j.1365-2125.2004.02059.x.

10. Corps AN, Harrall RL, Curry VA, Fenwick SA, Hazleman BL, Riley GP. Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1β in human tendon-derived cells: a potential mechanism of fluoroquinolone-induced tendinopathy. Arthritis Rheum. 2002;46(11):3034–3040. doi:10.1002/art.10617.

11. Corps AN, Harrall RL, Curry VA, Hazleman BL, Riley GP. Contrasting effects of fluoroquinolone antibiotics on the expression of the collagenases, matrix metalloproteinases (MMP)-1 and -13, in human tendon-derived cells. Rheumatology. 2005;44:1514–1517. doi:10.1093/rheumatology/kei087.

12. Duman E, Müller-Deubert S, Pattappa G, Stratos I, Sieber SA, Clausen-Schaumann H, Sarafian V, Shukunami C, Rudert M, Docheva D. Fluoroquinolone-mediated tendinopathy and tendon rupture. Pharmaceuticals. 2025;18(2):184. doi:10.3390/ph18020184.

13. Sendzik J, Shakibaei M, Schäfer-Korting M, Stahlmann R. Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. Toxicology. 2005;212(1):24–36. doi:10.1016/j.tox.2005.04.002.

14. Lowes DA, Wallace C, Murphy MP, Webster NR, Galley HF. The mitochondria targeted antioxidant MitoQ protects against fluoroquinolone-induced oxidative stress and mitochondrial membrane damage in human Achilles tendon cells. Free Radic Res. 2009;43(4):323–328. PMID: 19235604.

15. Pouzaud F, Bernard-Beaubois K, Thevenin M, Warnet JM, Hayem G, Rat P. In vitro discrimination of fluoroquinolone toxicity on tendon cells: involvement of oxidative stress. J Pharmacol Exp Ther. 2004;308(1):394–402. doi:10.1124/jpet.103.057984.

16. Simonin MA, Gegout-Pottie P, Minn A, Gillet P, Netter P, Terlain B. Pefloxacin-induced Achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen. Antimicrob Agents Chemother. 2000;44(4):867–872.

17. Kobayashi T, Sato T, Isozaki Y, Okubo M, Asoda S, Iwai T, Nogami S, Ito K. Decreased collagen XII expression and increased reactive oxygen species production in levofloxacin-treated tendon. Sci J Clin Med. 2024;13(4):63–70. doi:10.11648/j.sjcm.20241304.11.

18. Michalak K, Sobolewska-Włodarczyk A, Włodarczyk M, Sobolewska J, Woźniak P, Sobolewski B. Treatment of the fluoroquinolone-associated disability: the pathobiochemical implications. Oxid Med Cell Longev. 2017;2017:8023935. doi:10.1155/2017/8023935. PMID: 29147464.

19. Kaur K, Fayad R, Saxena A, Frizzell N, Chanda A. Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network. J Community Support Oncol. 2016;14(2):54–65.

20. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69(1):11–25.

21. Bisaccia DR, Aicale R, Tarantino D, Peretti GM, Maffulli N. Biological and chemical changes in fluoroquinolone-associated tendinopathies: a systematic review. Br Med Bull. 2019;130(1):39–49. doi:10.1093/bmb/ldz006.

22. Bernard-Beaubois K, Hecquet C, Hayem G, Rat P, Adolphe M. In vitro study of cytotoxicity of quinolones on rabbit tenocytes. Cell Biol Toxicol. 1998;14(4):283–292. doi:10.1023/A:1007435025616.

23. Menon A, Pettinari L, Martinelli C, Colombo G, Portinaro N, Dalle-Donne I, d’Agostino MC, Gagliano N. New insights in extracellular matrix remodeling and collagen turnover related pathways in cultured human tenocytes after ciprofloxacin administration. Muscles Ligaments Tendons J. 2013;3(3):122–131. doi:10.11138/mltj/2013.3.3.122. PMID: 24367771.

24. Arif AR, Yu J, Yin Q, Deng Y. An in vitro investigation of levofloxacin-induced cytotoxicity in rat bone marrow mesenchymal stem cells. Cureus. 2025;17(1):e77802. doi:10.7759/cureus.77802. PMID: 39991432.

25. Lewis T, Cook J. Fluoroquinolones and tendinopathy: a guide for athletes and sports clinicians and a systematic review of the literature. J Athl Train. 2014;49(3):422–427. doi:10.4085/1062-6050-49.2.09.

26. Zonta BM, Bet JL, Sebold LS, da Rocha FR, Fischer-Bacca CO, Baldo GV. Non-traumatic rupture of the gluteus medius associated with fluoroquinolone use: a case report. N Z Med J. 2025;138(1626).

27. Akali A, Niranjan N. Management of bilateral Achilles tendon rupture associated with ciprofloxacin: a review and case presentation. J Plast Reconstr Aesthet Surg. 2008. [Not located in indexed databases during final audit; confirm volume, pages, and DOI against the original or remove.]

28. Kim GK. The risk of fluoroquinolone-induced tendinopathy and tendon rupture: what does the clinician need to know? J Clin Aesthet Dermatol. 2010;3(4):49–54. PMID: 20725547.

29. Morales DR, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X. Relative and absolute risk of tendon rupture with fluoroquinolone and concomitant fluoroquinolone/corticosteroid therapy: population-based nested case–control study. Clin Drug Investig. 2019;39(2):205–213. doi:10.1007/s40261-018-0729-y.

30. Persson R, Jick S. Clinical implications of the association between fluoroquinolones and tendon rupture: the magnitude of the effect with and without corticosteroids. Br J Clin Pharmacol. 2019;85(5):949–959. doi:10.1111/bcp.13879.

31. Kucharczyk E, Kucharczyk N, Pawłuszkiewicz K. Impact of fluoroquinolones on tendon health: a comprehensive overview for the general population and athletes. Qual Sport. 2024;31:55763. doi:10.12775/QS.2024.31.55763.

32. Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf. 2013;12(4):497–505.

33. Wee I, Chin B, Syn N, Lee KS, Ng JJ, Choong AMTL. The association between fluoroquinolones and aortic dissection and aortic aneurysms: a systematic review and meta-analysis. Sci Rep. 2021;11:11073. doi:10.1038/s41598-021-90692-8.

34. Morales-Ojeda LA. The effect of fluoroquinolones on aortic aneurysm and dissection. Cureus. 2024;16(11):e74740. doi:10.7759/cureus.74740.

35. Wicherski J, Peltner J, Becker C, Schüssel K, Brückner G, Schlotmann A, Schröder H, Kern WV, Haenisch B. Fluoroquinolones and the risk of aortic aneurysm or dissection: a population-based propensity score-matched German cohort study. Pharmacotherapy. 2025;45(6):314–323. doi:10.1002/phar.70020.

36. Chen Q, Jiang Y, Shen Y, Huang X. Risk of aortic aneurysm/aortic dissection associated with fluoroquinolones use: a meta-analysis of cohort studies. Vascular. 2026;34(4):751–761. doi:10.1177/17085381261425725.

37. Wu ZY, Yang Y, Li ZL, Zhao WX, Chen ZG, Diao YP, Li YJ. Effects of fluoroquinolones on aortic aneurysm or dissection processes: a systematic review and meta-analysis. Rev Cardiovasc Med. 2026;27(3):43656. doi:10.31083/RCM43656.

38. Huh K, Kang M, Jung J. Lack of association between fluoroquinolone and aortic aneurysm or dissection. Eur Heart J. 2023;44(42):4476–4484. doi:10.1093/eurheartj/ehad627.

39. Wesley CD, Strange JE, Holt A, et al. Fluoroquinolones and the risk of aortic aneurysm or aortic dissection: evidence from a nationwide nested case–control study paralleled with matched experimental models. Eur Heart J Open. 2025;5(3):oeaf021. doi:10.1093/ehjopen/oeaf021.

40. Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:k678. doi:10.1136/bmj.k678. PMID: 29519881.

41. Zeng W, Liang Y, Huang S, Zhang J, Mai C, He B, Shi L, Liu B, Li W, Huang X, Li X. Ciprofloxacin accelerates angiotensin-II-induced vascular smooth muscle cells senescence through modulating AMPK/ROS pathway in aortic aneurysm and dissection. Cardiovasc Toxicol. 2024.

42. Landers ZD, Mazhar A. Fluoroquinolone-induced multisystem toxicity: a case report. Cureus. 2024;16(5):e61174. doi:10.7759/cureus.61174.

43. Wicherski J, Peltner J, Becker C, Schüssel K, Brückner G, Schlotmann A, Schröder H, Kern WV, Haenisch B. Fluoroquinolone-associated peripheral and central nervous system-related disorders: a large German claims-based cohort study. Eur J Neurol. 2026;33(4):e70585. doi:10.1111/ene.70585.

44. Miścă OM, Miścă LC, Huzum B, Neamțu AA, Cerbu S, Chioibaș DR, Crăiniceanu PZ, Motoc AGM. A prospective randomized pilot study on the efficacy of a dietary supplementation regimen of vitamin E and selenium for the prevention of fluoroquinolone-induced tendinopathy. Pharmaceuticals. 2025;18(4):575. doi:10.3390/ph18040575.

45. Furuta H, Yamada M, Nagashima T, Matsuda S, Nagayasu K, Shirakawa H, Kaneko S. Increased expression of glutathione peroxidase 3 prevents tendinopathy by suppressing oxidative stress. Front Pharmacol. 2023;14:1137952. doi:10.3389/fphar.2023.1137952.

46. Medsafe New Zealand. Systemic fluoroquinolones: update on regulatory actions and review of safety concerns. Medicines Adverse Reactions Committee, 201st meeting, 13 March 2025, agenda item 3.2.1. Available at: www.medsafe.govt.nz/committees/MARC/reports/201-3.2.1-Fluoroquinolones.pdf

47. Medsafe New Zealand. Systemic fluoroquinolone antibiotics: safety reminder. Prescriber Update. 2025;46(3):38–40. Published 4 September 2025.

Disclosures: The author reports no conflicts of interest relevant to this article.

Correspondence: Yoon Hang Kim MD MPH | Email: drkim@yoonhangkim.com | Web: www.yoonhangkim.com

Read more